04/08/2015 16:49:16 Cookie Policy Free Membership Login

Glaxosmithkline Share Chat - GSK

Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.00 +0.14% 1,402.00 1,401.50 1,402.50 1,412.50 1,395.00 1,401.00 8,073,664 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 23,006.0 2,968.0 57.3 24.5 68,193.37

Glaxosmithkline Share Discussion Threads

Showing 11100 to 11125 of 11125 messages
Post New Message
Chat Pages: 445  444  443  442  441  440  439  438  437  436  435  434  >>
Damn. I'm too old to retire young :)hiriam007
Oh dear if Monty is in then thats a bad sign. Lets hope that this thread is not ruined by him spamming this with baseless ramps. Remember if everyone who was on this thread bought or sold their entire holdings here it wouldn't scratch the surface either way. Have to think about these on a 3 year view - if they can get some new products to Market and the HIV sales replace the Advair losses we could easily get back to £16. Add in the dividends and thats a decent 10% return a year. If I could get that across the board (obv not guaranteed here) then I could retire early..dr biotech
monty, your ability to move the SP's of UKX stocks is unique )essentialinvestor
GSK and Astra Zenecca the ones in the FTSE100 to buy.montyhedge
Yep - I added yesterday as looks like breaking back up on reasonable volumedavr0s
Can see these at 1450 by XD date. Chart is looking very bullish, certainly a retest of this years highs must be odds on.my retirement fund
Nice little rise through 1400p Anyone prepared to sell, with a 19p dividend qualifying in 9 days time? ...... ;0)tradermichael
Huh!!! so much for my "Institutional" buying opportunity to add when there appeared to be a mega sell of 3.33million shares at 1394p at 13.02 (OT trade). That's over £46 million!!! Perhaps I should be more humble/balanced in my predictions?cyberian
I think we may get a good run-up in the share price through to the November R&D presentation as there are those 42 medical trials at or close to their final stages. The recent fall to low 1325p was a bit overdone and may have allowed a few Institutions to add? The shares were talked down with little substance to justify this imho, however,some may still disagree about the new strategy agreed by the GSK Board of Directors. Interesting times ahead as many are still looking for new treatments/vaccines, and GSK has an excellent pipe-line. Just got to be a little patient.cyberian
TM - Xdiv for Q4 is 18 Feb 2016 I think. Whether the "special" XDiv is the same date I'm not sure. Anyone enlighten us? NRnik rosa
For the 'special' dividend at the end of the GSK financial year, does anyone know what the qualifying date is, please?tradermichael
I see very little attraction with CNA, thanks for the reply.essentialinvestor
EI: anhar, is CNA off you list now?, if you were holding... Have never held it. I hold two energy utilities, NG. and SSE.anhar
From Motley Fool: Drugs giant GlaxoSmithKline (LSE: GSK) has seen its share price rise since releasing its half-year report on Wednesday, and this positive trend was continuing in Thursday’s session with a further 0.9% gain. The business advised that core revenues had advanced 6% during April-June, to £5.9bn, thanks to accelerating strength in its Vaccines and Consumer Healthcare divisions. While patent lapses remain a huge problem, GlaxoSmithKline’s R&D team continues to deliver the next raft of sales drivers, and currently has 40 new drugs in mid-to-late-stage development. On top of this, its new Tivicay and Triumeq HIV-combating drugs are already proving extremely lucrative, and generated £294m of sales during the six-month period. Given GlaxoSmithKline’s red-hot development pipeline, the City expects the firm to bounce from a 19% earnings decline this year — the fourth successive fall if realised — to punch an 11% advance in 2016. Consequently the Brentford firm sees a P/E rating of 17.4 times for 2015 fall to just 15.7 times for 2016, just above the benchmark of 15 times that marks decent value for money. And GlaxoSmithKline’s vow to pay out dividends of 80p per share through to the close of 2017 produces a hefty yield of 5.8%. With healthcare demand galloping across the globe I reckon GlaxoSmithKline’s rejuvenated pipeline should provide brilliant earnings growth.tradermichael
Does anyone know why Soc Gen and Deutsche differ on GSK outlook, as per Alliance comment on subscriber forum?cyberian
anhar, is CNA off you list now?, if you were holding. Not sure what Woodford sees in CNA, I changed to First Utility and made savings. I see the first "not for profit operator" now coming in to the utility sector in Scotland.essentialinvestor
As a direct holding its about 5% of my total. Given that my woodford is about double that, plus a substantial FTSE tracker and others that possibly hold them its probably closer to 8 or 9%. But I don't see that as being an issue. Cricket is not going as well as I hoped. 100 lead is not insignificant though if we can get it.dr biotech
I've added more in here today. Makes it my largest holding, other than woodford. I just want to have more income from holdings. This will give me a dividend income in total of more than £10k. Nowhere near enough to retire on but that is still way in the distance. I live principally from my large diversified income port and have been running it for years, since long before I gave up working, but I'd advise not to overweight any share at purchase because that is unnecessarily risky for income, should that share cut divis. And that is no matter how ostensibly attractive the share might be. If you need the income, it needs to be done with the lowest risk possible, given that equity income is risk income. Market values alter constantly so some shares go well over average in time and some below, that's just due to fluctuation in cap values in which I have no interest. But if I add to a holding or buy a new one, I never invest more than would bring it up to average value at that point. To over invest in a share is inviting excess risk to income in my opinion, however tempting it may appear.anhar
Never mind, England now 23 runs ahead ....tradermichael
Essentially the co decided that the £4bn was better off securing the 80 dividend for the next 3 years (with an extra 20p this year) rather than a one off payment. Something I agree with as it brings some certainty and they should be able to pay off some debt. I see the market has just caught on to the change in my holding and acted accordingly. Normally that means a massive slump.dr biotech
RNS on 2/3/15 refers to previously announced return of capital of £4billion. Can anyone enlighten me as to how that has become £1billion?cashpo1nt
I live very modestly, a cup of tea and Emmerdale is my idea of a good evening, with a couple of glasses of red )essentialinvestor
I've added more in here today. Makes it my largest holding, other than woodford. I just want to have more income from holdings. This will give me a dividend income in total of more than £10k. Nowhere near enough to retire on but that is still way in the distance.dr biotech
No worries.supermarky
Appreciated mark.essentialinvestor
Chat Pages: 445  444  443  442  441  440  439  438  437  436  435  434  >>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 150804 16:49